Eligo Bioscience Awarded as Technology Pioneer by World Economic Forum

Health & Medicine
by
|
June 14, 2017

Paris, June 14, 2017Eligo Bioscience, the Paris-based start-up that seeks to enable precise engineering of the microbiome, was chosen among hundreds of candidates as one of the World Economic Forum’s “technology pioneers,” a selection of the world’s most innovative companies. Eligo was founded by four scientists: Dr. Xavier Duportet (MIT, INRIA), Dr. David Bikard (Rockefeller University, the Pasteur Institute), Professor Timothy Lu (MIT), and Professor Luciano Marraffini (Rockefeller University). Eligo is creating a platform technology that will translate the vast amounts of research on human and animal microbiomes into breakthrough treatments for unmet medical needs – including combating antibiotic resistance.The World Economic Forum’s Technology Pioneers community are early-stage companies from around the world that are involved in the design, development and deployment of new technologies and innovations, and are poised to have a significant impact on business and society. The 30 technology pioneers that made it to the final selecti on are active in artificial intelligence, augmented reality, autonomous vehicles, biotechnology, blockchain, cybersecurity, the (industrial) internet of things, and other pioneering technologies.Following Eligo’s selection as Technology Pioneer, CEO Xavier Duportet was invited to attend the Annual Meeting in Davos, in January 2018, and hopes to continue participating in dedicated Technology Pioneer community events in the course of the next two years.“We welcome Eligo Bioscience in this group of extraordinary pioneers,” says Fulvia Montresor, Head of Technology Pioneers at the World Economic Forum. “We hope that thanks to this selection, the World Economic Forum can facilitate greater collaboration with business leaders, governments, civil society and other relevant individuals to accelerate the development of technological solutions to the world’s greatest challenges.”“It is a privilege for Eligo’s work to have been recognized by the World Economic Forum,” said CEO and Cofounder Dr. Duportet. “Eligo’s technology could one day give us the ability to precisely engineer the microbiomes of humans and animals. This ability will be an indispensable component of personalized medicine, preventive care, and disease treatment. We hope that being awarded as a Techology Pioneer will allow us to meet and partner with leaders across many industries and institutions to bring our technology to market more quickly.”The Technology Pioneers were selected by a selection committee of more than 60 academics, entrepreneurs, venture capitalists and corporate executives. Notable members of the committee include Geoffrey Moore (Adviser, Geoffrey Moore Consulting, USA), Yossi Vardi (Chairman, International Technologies, Israel) and Lee Sang-Yup (Distinguished Professor and Dean, Korea Advanced Institute of Science and Technology, Republic of Korea). The committee based its decisions on criteria including innovation, potential impact and leadership. Past recipients include Airbnb, Google, Kickstarter, Mozilla, Palantir Technologies, Scribd, Spotify, Twitter and Wikimedia.All info on this year’s Technology Pioneers can be found here: http://wef.ch/techpioneers17More information on past winners can be found here.About Eligo Bioscience: Eligo Bioscience is an early-stage biomedical start-up developing the next generation of antimicrobials for precise microbiome engineering. It is based in Paris, France and is developing “eligobiotics” to address unmet medical needs in areas such as infectious and microbiome-associated diseases.About World Economic Forum: The World Economic Forum, committed to improving the state of the world, is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business and other leaders of society to shape global, regional and industry agendas. (www.weforum.org).

Related Articles

No items found.